Operating profit before deduction of amortization: KalVista Pharmaceuticals, Inc. (KALV)
The transition to the commercialization of drugs for the treatment of HAE is driving growth, as evidenced by EBITDA fluctuations, where the 0.00 mark indicates the level of operational efficiency. KalVista Pharmaceuticals (KALV) relies on the development of convenient, high-margin oral medications. Revenues are based on the therapy of rare pathologies reimbursed by the insurance sector. This trend underscores the resilience of the company's fundamental indicators.
KalVista Pharmaceuticals, Inc. (KALV) - metric breakdowns and financial figures
- stock value and consensus price forecast:
- company stock exchange capitalization indicators:
- shareholders' equity book value data:
- debt level and financial liquidity data:
Debt to Equity Ratio KalVista Pharmaceuticals|KALV - Long-Term Debt to Capital|Current Liabilities to Capital KalVista Pharma|KALV - Company Debts|Debts to Book Capitalization KalVista Pharmaceuticals|KALV - Company Long-Term Debts|Company Short-Term Debts KalVista Pharmaceuticals|Quick Liquidity kalvista.com
- earnings and multiples data:
KALV - Net Income|Expected Profit KalVista Pharmaceuticals|KALV - P/E Multiple|Market Cap to Projected Earnings kalvista.com|KALV - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio KalVista Pharmaceuticals|KALV - Operating profit before deduction of amortization|Earnings per share for the last four quarters KalVista Pharmaceuticals|KALV - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth kalvista.com|KALV - Net earnings per share growth this year|Expected earnings per share trend next year KalVista Pharmaceuticals
- sales and revenue indicators:
Analysis of all company metrics:KALV (KalVista Corp)
For KalVista Pharmaceuticals (KALV), a developer of hereditary angioedema therapies, this indicator reflects the daily cash flow from core operations. The metric measures net operating inflows, allowing for the identification of business stagnation or growth phases. By analyzing the EBITDA_Co trend, an investor can track the company's transition toward financial stability. For a biotech firm, this is critical while awaiting the approval of sebetralstat and facing competition from injectable alternatives. Confirmation of an upward trend will serve as a signal to invest.
Who KalVista Pharmaceuticals competes with
Operating income before deduction of amortization argenx BVBA (ARGX)|BNTX - Profit before payment of interest, taxes and amortization|Abivax S.A. (ABVX) - Operating profit before deduction of amortization|ADMA Biologics, Inc. (ADMA) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization Protagonist Therapeutics, Inc.|Operating profit before deduction of amortization IMVT|Operating profit EBITDA Kiniksa Corp|Profit before payment of interest, taxes and amortization Grifols, S.A. (GRFS)|adaptivebiotech.com - Operating profit before amortization|Operating profit EBITDA CLDX (Celldex Therapeutics, Inc.)|Aurinia Pharmaceuticals Inc (AUPH) - Profit before interest, taxes and amortization|BCRX - Profit before payment of interest, taxes and amortization|VERA - Operating profit EBITDA|DNTH: Operating profit EBITDA|pharvaris.com (PHVS) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization AbCellera Biologics Inc.|Profit before payment of interest, taxes and amortization TRML|Operating profit before deduction of amortization PGEN (Intrexon)|Profit before payment of interest, taxes and amortization PHAR (Pharming Corp)|Operating profit EBITDA NKTR (Nektar Therapeutics)|Operating income before deduction of amortization upstreambio.com (UPB)|ZBIO - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization Immunome Inc IMNM|GOSS (Gossamer Corp) - Operating profit before deduction of amortization|SEPN: Company profit before taxes, interest and amortization|PVLA (Pieris Pharmaceuticals) - Operating profit EBITDA|Operating profit EBITDA savarapharma.com|Operating profit before deduction of amortization RIGL (Rigel Pharmaceuticals, Inc.)|ANAB (AnaptysBio Inc) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Astria Pharma ATXS|ENGN (enGene Corp) - Profit before deduction of interest, taxes, depreciation and amortization|RAPT Therapeutics - Operating profit EBITDA|Income before deduction of interest, taxes and amortization JBIO (Aerovate Therapeutics Inc)|ACRS: Operating profit EBITDA|Kyverna Therapeutics Inc. (KYTX) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization Tiziana Life Sciences PLC|CABA: Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Ventyx Biosciences (VTYX)|Operating profit before deduction of amortization theratech.com THTX|Operating profit EBITDA AVTX (Avalo Therapeutics)|Operating profit EBITDA Eledon Pharmaceuticals Inc. ELDN|Agenus Inc - Operating profit EBITDA|Climb Bio, Inc (CLYM) - Operating profit before deduction of amortization|ZURA: Operating profit EBITDA|Profit before interest, taxes and amortization atyrpharma.com (ATYR)|Operating profit before deduction of amortization ADAG|Operating profit EBITDA Ikena Oncology, Inc.|Operating profit before deduction of amortization STTK (Shattuck Labs, Inc.)|Company profit before taxes, interest and amortization EQ|Operating profit EBITDA CNTB (Connect Biopharma Holdings Limited)|Operating income before deduction of amortization Immunic Therapeutics (IMUX)|Atara Biotherapeutics Inc - Operating profit EBITDA|InflaRx N.V. (IFRX) - Operating profit before deduction of amortization|XFOR: Operating profit EBITDA|Adicet Bio, Inc. (ACET) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization Celularity Inc|Profit before payment of interest, taxes and amortization INMB|Profit before payment of interest, taxes and amortization Barinthus Biotherapeutics plc (BRNS)|Operating income before deduction of amortization Kezar Life Sciences Inc.|Profit before payment of interest, taxes and amortization SAB Biotherapeutics, Inc SABS|Operating profit EBITDA Akari Therapeutics, Plc AKTX|Enlivex Therapeutics, Ltd. - Operating profit EBITDA|QTTB - Operating profit EBITDA|GeoVax (GOVX) - Profit before payment of interest, taxes and amortization|EDSA (Edesa Biotech Inc) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization IBIO|Profit before payment of interest, taxes and amortization CARM|Profit before payment of interest, taxes and amortization XTL Biopharmaceuticals (XTLB)|BOLT: Profit before deduction of interest, taxes, depreciation and amortization|Operating profit EBITDA HCWB (HCW Biologics)|Income before deduction of interest, taxes and amortization APVO|AIM ImmunoTech Inc. - Operating profit EBITDA|ADTX - Operating profit EBITDA|GRI Bio, Inc. (GRI) - Profit before payment of interest, taxes and amortization|xortx.com - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Vyome Holdings|Operating profit before deduction of amortization Revelation Biosciences Inc (REVB)|Operating profit EBITDA INDP|Operating profit EBITDA BiondVax Pharmaceuticals (SCNI)|CalciMedica - Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization AFMD|Allakos Therapeutics - Operating profit EBITDA|Operating income before deduction of amortization HOOKIPA Pharma Inc. HOOK|igmbio.com (IGMS) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization iTeos Pharma|Profit before payment of interest, taxes and amortization Ocean Biomedical, Inc.|Operating profit before deduction of amortization tcbiopharm.com (TCBP)|Operating profit before deduction of amortization THRD (Third Harmonic Bio, Inc.)
